259 related articles for article (PubMed ID: 35131878)
21. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
22.
Maddalena M; Mallel G; Nataraj NB; Shreberk-Shaked M; Hassin O; Mukherjee S; Arandkar S; Rotkopf R; Kapsack A; Lambiase G; Pellegrino B; Ben-Isaac E; Golani O; Addadi Y; Hajaj E; Eilam R; Straussman R; Yarden Y; Lotem M; Oren M
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34088837
[TBL] [Abstract][Full Text] [Related]
23. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation.
Müller F; Lim JKM; Bebber CM; Seidel E; Tishina S; Dahlhaus A; Stroh J; Beck J; Yapici FI; Nakayama K; Torres Fernández L; Brägelmann J; Leprivier G; von Karstedt S
Cell Death Differ; 2023 Feb; 30(2):442-456. PubMed ID: 36443441
[TBL] [Abstract][Full Text] [Related]
24. The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.
Muniz VP; Barnes JM; Paliwal S; Zhang X; Tang X; Chen S; Zamba KD; Cullen JJ; Meyerholz DK; Meyers S; Davis JN; Grossman SR; Henry MD; Quelle DE
Mol Cancer Res; 2011 Jul; 9(7):867-77. PubMed ID: 21636682
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic
Kim MP; Li X; Deng J; Zhang Y; Dai B; Allton KL; Hughes TG; Siangco C; Augustine JJ; Kang Y; McDaniel JM; Xiong S; Koay EJ; McAllister F; Bristow CA; Heffernan TP; Maitra A; Liu B; Barton MC; Wasylishen AR; Fleming JB; Lozano G
Cancer Discov; 2021 Aug; 11(8):2094-2111. PubMed ID: 33839689
[TBL] [Abstract][Full Text] [Related]
27. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.
Abrams SL; Duda P; Akula SM; Steelman LS; Follo ML; Cocco L; Ratti S; Martelli AM; Montalto G; Emma MR; Cervello M; Rakus D; Gizak A; McCubrey JA
Cells; 2022 Feb; 11(5):. PubMed ID: 35269416
[TBL] [Abstract][Full Text] [Related]
28. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma.
Wang S; Xiong Y; Luo Y; Shen Y; Zhang F; Lan H; Pang Y; Wang X; Li X; Zheng X; Lu X; Liu X; Cheng Y; Wu T; Dong Y; Lu Y; Cui J; Jia X; Yang S; Wang L; Wang Y
EMBO Mol Med; 2024 May; 16(5):1115-1142. PubMed ID: 38570712
[TBL] [Abstract][Full Text] [Related]
30. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B
Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125
[TBL] [Abstract][Full Text] [Related]
31. Exploiting the ferroaddiction of pancreatic cancer cells using Fe-doped nanoparticles.
Lomphithak T; Sae-Fung A; Sprio S; Tampieri A; Jitkaew S; Fadeel B
Nanomedicine; 2024 Jan; 55():102714. PubMed ID: 38738528
[TBL] [Abstract][Full Text] [Related]
32. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
[TBL] [Abstract][Full Text] [Related]
33. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
34. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
35. Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice.
Görgülü K; Diakopoulos KN; Ai J; Schoeps B; Kabacaoglu D; Karpathaki AF; Ciecielski KJ; Kaya-Aksoy E; Ruess DA; Berninger A; Kowalska M; Stevanovic M; Wörmann SM; Wartmann T; Zhao Y; Halangk W; Voronina S; Tepikin A; Schlitter AM; Steiger K; Artati A; Adamski J; Aichler M; Walch A; Jastroch M; Hartleben G; Mantzoros CS; Weichert W; Schmid RM; Herzig S; Krüger A; Sainz B; Lesina M; Algül H
Gastroenterology; 2019 Jan; 156(1):203-217.e20. PubMed ID: 30296435
[TBL] [Abstract][Full Text] [Related]
36. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
37. IQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis.
Li JH; McMillan RH; Begum A; Gocke CB; Matsui W
Pancreas; 2019 Jan; 48(1):94-98. PubMed ID: 30540680
[TBL] [Abstract][Full Text] [Related]
38. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
[TBL] [Abstract][Full Text] [Related]
39. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
40. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
